264 related articles for article (PubMed ID: 34958112)
21. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.
Patel K; Lamm R; Altshuler P; Dang H; Shah AP
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942580
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
23. Cancer cell-intrinsic STING is associated with CD8 + T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma.
Zhang Y; Zhai Q; Feng X; Chen D; Lu Y; Hu J; Xie H; Zhou L; Wu J; Zheng S
Clin Transl Oncol; 2021 Jul; 23(7):1314-1324. PubMed ID: 33502741
[TBL] [Abstract][Full Text] [Related]
24. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
[TBL] [Abstract][Full Text] [Related]
25. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM; Lee RY; Goh S; Tay ISY; Lim X; Lee B; Chew V; Li H; Tan B; Lim S; Lim JCT; Au B; Loh JJH; Saraf S; Connolly JE; Loh T; Leow WQ; Lee JJX; Toh HC; Malavasi F; Lee SY; Chow P; Newell EW; Choo SP; Tai D; Yeong J; Lim TKH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847986
[TBL] [Abstract][Full Text] [Related]
27. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
28. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
29. Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody.
Li Z; Li B; Peng D; Xing H; Wang G; Li P; Wang J; Ye G; Chen J
Int J Oncol; 2018 Jun; 52(6):2079-2092. PubMed ID: 29620156
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma.
Zhang F; Liu W; Meng F; Jiang Q; Tang W; Liu Z; Lin X; Xue R; Zhang S; Dong L
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272562
[TBL] [Abstract][Full Text] [Related]
31. Single sample scoring of hepatocellular carcinoma: A study based on data mining.
Zhu D; Wu ZH; Xu L; Yang DL
Int J Immunopathol Pharmacol; 2021; 35():20587384211018389. PubMed ID: 34053310
[TBL] [Abstract][Full Text] [Related]
32. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma.
Garnelo M; Tan A; Her Z; Yeong J; Lim CJ; Chen J; Lim KH; Weber A; Chow P; Chung A; Ooi LL; Toh HC; Heikenwalder M; Ng IO; Nardin A; Chen Q; Abastado JP; Chew V
Gut; 2017 Feb; 66(2):342-351. PubMed ID: 26669617
[TBL] [Abstract][Full Text] [Related]
33. CD74
Xiao N; Li K; Zhu X; Xu B; Liu X; Lei M; Sun HC
Cancer Immunol Immunother; 2022 Jan; 71(1):57-69. PubMed ID: 34009409
[TBL] [Abstract][Full Text] [Related]
34. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
35. HBV induced hepatocellular carcinoma and related potential immunotherapy.
Jia L; Gao Y; He Y; Hooper JD; Yang P
Pharmacol Res; 2020 Sep; 159():104992. PubMed ID: 32505833
[TBL] [Abstract][Full Text] [Related]
36. SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma.
Wang Z; Pan B; Su L; Yu H; Wu X; Yao Y; Zhang X; Qiu J; Tang N
Cell Oncol (Dordr); 2024 Apr; 47(2):513-532. PubMed ID: 38055116
[TBL] [Abstract][Full Text] [Related]
37. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
[TBL] [Abstract][Full Text] [Related]
38. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
39. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma.
Li H; Wang J; Liu H; Lan T; Xu L; Wang G; Yuan K; Wu H
Aging (Albany NY); 2020 Feb; 12(4):3451-3472. PubMed ID: 32087064
[TBL] [Abstract][Full Text] [Related]
40. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
